Vaxcyte (PCVX) Q4 FY25 earnings call

Vaxcyte closed FY25 with significant progress in its pneumococcal conjugate vaccine franchise, initiating three pivotal Phase III studies for VAX-31 adult and completing enrollment for the VAX-31 infant Phase II study. The company also fortified its manufacturing and commercial readiness, supported by a robust balance sheet and recent equity offering, providing runway through 2028. This positions Vaxcyte for a catalyst-rich period with multiple clinical readouts expected over the next 12-18 months, including the resumption of its VAX-A1 program.